A gender discrepancy exists in the incidence of both urothelial and kidney carcinomas, with more men presenting with these cancers than women. Men have a threefold greater risk of developing bladder cancer than women, but female gender has been identified as an independent adverse prognostic factor for both recurrence and progression of this disease.10/08/2015
Publication date: Available online 9 August 2018Source: Actas Urológicas Españolas (English Edition)Author(s): F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, J. Cózar-OlmoAbstractObjectiveTo put forth new findings of urologic oncology with an impact on clinical practice presented during 2017 in the main annual meetings.MethodsThis document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee.ResultsAmong…
In this study we selected 58 consecutive NSCLC surgical specimens that underwent pathologic examination from January 2014 to July 2015. Using a tissue microarray approach we evaluated the IHC expression of PD-L1 in tumor-infiltrating lymphocytes and tumor cells (TCs) and compared the ICH staining with tumor histology, grade and the age of the tissue blocks. The main new finding was the fading of PD-L1 IHC expression in TCs in tissues processed in 2014 compared with 2015. PD-L1 expression in tumor-infiltrating lymphocytes in the 2 years was similar. We also found a significant higher immunoreactivity of TCs in high grade NS…
In the last decade, immunotherapy has completely changed the therapeutic armamentarium of patients with genitourinary tumors. In particular, the approval of anti-Programmed-death-1 (PD-1) agents in patients with renal cell carcinoma (RCC) and bladder cancer (BC) has increased their life expectancy, with a generally tolerated toxicity profile. On the contrary, patients with prostate cancer (PCa) seem to scarcely benefit from this strategy.
AbstractAimsTo investigate the role of Radiation Oncology in the management of genito-urinary (GU) cancer excluding prostate and penile cancer.MethodsThe questionnaire was focused on the evaluation of the degree of involvement of radiation oncologists in the work-up of bladder, renal cell carcinoma and testicular cancer (TC).ResultsEighty-eight radiation oncologists completed the survey. The majority (85.4%) of participating radiation oncologists were senior consultants (> 5 years of experience). Sixty-four (73.6%) carried out a multidisciplinary tumor board discussion of GU cases, while 23 (26.4%) did not….
Checkpoint inhibitors, such as cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) and programmed cell death-1 (PD-1) monoclonal antibodies have changed profoundly the treatment of melanoma, renal cell carcinoma, non-small cell lung cancer, Hodgkin lymphoma, and bladder cancer. Currently, they are tested in various tumor entities as monotherapy or in combination with chemotherapies or targeted therapies. However, only a subgroup of patients benefit from checkpoint blockade (combinations).07/11/2018
Authors: Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R
INTRODUCTION: Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into…
Developments in urologic oncology “OncoForum”: The best of 2017.
Actas Urol Esp. 2018 Jun 20;:
Authors: Gómez-Veiga F, Alcaraz-Asensio A, Burgos-Revilla J, Cózar-Olmo J
OBJECTIVE: To put forth new findings of urologic oncology with impact on clinical practice presented during 2017 in the main annual meetings.
METHODS: This document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum commit…
Contributors : Naohiko Seki ; Takayuki AraiSeries Type : Expression profiling by arrayOrganism : Homo sapiensTo identify differentially expressed genes by anti cancer treatments (microRNAs or siRNAs) in human cancer, several cell lines ( pancreatic cancer, renal cell carcinoma, oral squamous cell carcinoma, prostate cancer and bladder cancer) were subjected to Agilent whole genome microarrays.
Authors: Yang Y, Xu J, Zhang Q
The aim of the present study was to establish a simple step magnetic particles (MPs) based chemiluminescence enzyme immunoassay (CLEIA) for the detection of urinary survivin, and to investigate the diagnostic value of urinary survivin and lysosome-associated protein transmembrane-4β (LAPTM4B) in bladder cancer (BC) and renal cell carcinoma (RCC). The MPs-based CLEIA was developed on the basis of a double antibodies sandwich immunoreaction and luminol-H2O2 chemiluminescence system. The parameters of the method were optimized and evaluated. Urine samples were obtained from…
Conclusions: A comprehensive analysis revealed the changes in the expression of different KLK genes associated with specific cancers and highlighted their potential as a diagnostic and prognostic tool.
PMID: 29707153 [PubMed]